Tevogen Provided Updates At J.P. Morgan Healthcare Conference

Tevogen Bio Holdings Inc. -0.45%

Tevogen Bio Holdings Inc.

TVGN

4.46

-0.45%

Pipeline Expansion Across Multiple Indications:

Building on its SARS-CoV-2 proof-of-concept clinical experience, Tevogen completed T cell target identification for five additional HLA restrictions, significantly expanding potential patient coverage for its SARS-CoV-2-specific CTL product.

Tevogen also advanced target discovery and preclinical activities supporting CTL therapies addressing:

  • Epstein-Barr virus (EBV) associated lymphomas
  • Chronic hepatitis B, including programs focused on prevention of virus-associated hepatic diseases and cancer
  • Human Papilloma Virus (HPV) related cancers
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.